Nasdaq Apgn News Today

Apexigen, Inc. (NASDAQ:APGN – Get Free Report) was the target of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 64,500 shares, a decline of 18.8% from the July 15th total of 79,400 shares. Approximately 0.3% of the shares of the company are sold […]

Apexigen (NASDAQ:APGN – Get Rating) and Catalyst Biosciences (NASDAQ:CBIO – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership. Volatility and Risk Apexigen has a beta of 3.94, suggesting […]

- Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in...

Apexigen, Inc. (NASDAQ:APGN – Get Rating) shares were up 3.5% on Wednesday . The company traded as high as $0.52 and last traded at $0.52. Approximately 17,221 shares were traded during trading, a decline of 99% from the average daily volume of 2,086,545 shares. The stock had previously closed at $0.50. Analyst Ratings Changes A […]

-Ongoing Phase 2 trial in collaboration with Columbia University demonstrated that sotigalimab (sotiga) in combination with doxorubicin achieved a median...

-Sotigalimab in combination with neoadjuvant chemoradiation induced higher pathologic complete response rates, an important predictor of survival, in...